Join Growin Stock Community!

Estrella immunopharma, inc.ESLAW.US Overview

US StockHealthcare
(No presentation for ESLAW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ESLAW AI Insights

ESLAW Overall Performance

ESLAW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ESLAW Recent Performance

-

Estrella immunopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ESLAW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ESLAW Key Information

ESLAW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ESLAW Profile

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Price of ESLAW

ESLAW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ESLAW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.36
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ESLAW's latest earnings report released?

    The most recent financial report for Estrella immunopharma, inc. (ESLAW) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ESLAW's short-term business performance and financial health. For the latest updates on ESLAW's earnings releases, visit this page regularly.

  • How much cash does ESLAW have?

    At the end of the period, Estrella immunopharma, inc. (ESLAW) held Total Cash and Cash Equivalents of 1.32M, accounting for 0.44 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ESLAW's EPS continuing to grow?

    According to the past four quarterly reports, Estrella immunopharma, inc. (ESLAW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.15. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ESLAW?

    Estrella immunopharma, inc. (ESLAW)'s Free Cash Flow (FCF) for the period is -414.88K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 42.32% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ESLAW?

    The latest valuation data shows Estrella immunopharma, inc. (ESLAW) has a Price-To-Earnings (PE) ratio of -10.48 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.